+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cardiac Biomarker Diagnostic Kits Market (2021-2026) by Product, Indication, Testing, End-User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 188 Pages
  • June 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5410394
The Global Cardiac Biomarker Diagnostic Kits Market is estimated to be USD 3.2 Bn in 2021 and is expected to reach USD 5.04 Bn by 2026, growing at a CAGR of 9.5%.



Market Dynamics

Due to the increasing geriatric population, unhealthy lifestyle among individuals, high smoking & alcohol consumption inevitably leads to rising incidences of cardiovascular diseases, which is majorly driving the market growth. Other important drivers are increasing awareness of early detection of diseases coupled with rising healthcare spending in emerging countries. Additionally, the increasing popularity of point-of-care testing has boosted the market revenue. However, the low availability of cardiac biomarker diagnostic test kits to diagnose strokes is expected to hinder the market.
The rising investment from public and private organizations for research on cardiac biomarkers is anticipated to create new opportunities for the market.

Market Segmentation

The Global Cardiac Biomarker Diagnostic Kits Market is segmented further based on Product, Indication, Testing, End-User, and Geography.

By Product, the market is classified into Brain Natriuretic Peptide (BNPs) Test Kits, Creatine Kinase MB (CK-MB) Test Kits, Troponin (I&T) Tests Kits, Myoglobin Test Kits, and Other Test Kits. Amongst all, the Troponin (I&T) Tests Kits segment is estimated to hold the highest market share during the forecast period.

By Indication, the market is classified as Acute Coronary Syndrome, Acute Myocardial Infarction, Congestive Heart Failure, and Others. Amongst all, the Acute Coronary Syndrome segment is estimated to hold the highest market share during the forecast period.

By Testing, the market is classified as Laboratory Testing and Point of Care Testing. Amongst the two, the Laboratory Testing segment is estimated to hold the highest market share during the forecast period.

By End-User, the market is classified as Hospitals, Clinics, Diagnostic Laboratories, and Others. Amongst the two, the Hospitals segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Roche has announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). - 29th April 2021

Company Profiles

Some of the companies covered in this report are Siemens AG, Beckman Coulter Inc., Becton, Dickinson, and Company, Life Diagnostic, Roche Diagnostic, etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Cardiac Biomarker Diagnostic Kits Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Cardiac Biomarker Diagnostic Kits Market

What is the estimated value of the Global Cardiac Biomarker Diagnostic Kits Market?

The Global Cardiac Biomarker Diagnostic Kits Market was estimated to be valued at $3200 Million in 2021.

What is the growth rate of the Global Cardiac Biomarker Diagnostic Kits Market?

The growth rate of the Global Cardiac Biomarker Diagnostic Kits Market is 9.5%, with an estimated value of $5040 Million by 2026.

What is the forecasted size of the Global Cardiac Biomarker Diagnostic Kits Market?

The Global Cardiac Biomarker Diagnostic Kits Market is estimated to be worth $5040 Million by 2026.

Who are the key companies in the Global Cardiac Biomarker Diagnostic Kits Market?

Key companies in the Global Cardiac Biomarker Diagnostic Kits Market include Abbott Laboratories, Alere, Atlas Medical, Beckman Coulter, Becton, Dickinson and Company, Bio, Rad Laboratories, bioMérieux and Danaher.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Increasing Burden of Cardio-Vascular Diseases and Demand for Early Detection
4.1.2 Rising Geriatric Population
4.1.3 Integration of Cardiology & IT
4.1.4 Increasing Trend of Point-of-Care Testing (POCT)
4.2 Restraints
4.2.1 Tedious Government Approval Procedures
4.2.2 Unfavorable Reimbursement Policies
4.3 Opportunities
4.3.1 Growing Funding from Public and Private Organizations for Advancement in Cardiac Biomarker Diagnostic
4.3.2 Improving Healthcare Infrastructure in Developing Countries
4.4 Challenges
4.4.1 Product Recalls
4.4.2 Side-Effects Associated with Some Biomarkers
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Cardiac Biomarker Diagnostic Kits Market, By Product
6.1 Introduction
6.2 Brain Natriuretic Peptide (BNPs) Test Kits
6.3 Creatine Kinase MB (CK-MB) Test Kits
6.4 Troponin (I&T) Tests Kits
6.5 Myoglobin Test Kits
6.6 Other Test Kits
7 Global Cardiac Biomarker Diagnostic Kits Market, By Indication
7.1 Introduction
7.2 Angina Pectoris
7.3 Acute Myocardial Infarction
7.4 Congestive Heart Failure
7.5 Others
8 Global Cardiac Biomarker Diagnostic Kits Market, By Testing
8.1 Introduction
8.2 Laboratory Testing
8.3 Point of Care Testing
9 Global Cardiac Biomarker Diagnostic Kits Market, By End-User
9.1 Introduction
9.2 Hospitals
9.3 Clinics
9.4 Diagnostic Laboratories
9.5 Others
10 Global Cardiac Biomarker Diagnostic Kits Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 South America
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Chile
10.3.4 Colombia
10.4 Europe
10.4.1 UK
10.4.2 France
10.4.3 Germany
10.4.4 Italy
10.4.5 Spain
10.4.6 Netherlands
10.4.7 Sweden
10.4.8 Russia
10.4.9 Rest of Europe
10.5 Asia-Pacific
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 Indonesia
10.5.5 Malaysia
10.5.6 South Korea
10.5.7 Australia
10.5.8 Sri Lanka
10.5.9 Thailand
10.5.10 Rest of APAC
10.6 Middle-East and Africa
10.6.1 Qatar
10.6.2 Saudi Arabia
10.6.3 South Africa
10.6.4 United Arab Emirates
11 Competitive Landscape
11.1 Competitive Quadrant
11.2 Market Share Analysis
11.3 Strategic Initiatives
11.3.1 M&A and Investments
11.3.2 Partnerships and Collaborations
11.3.3 Product Developments and Improvements
12 Company Profiles
12.1 Abbott Laboratories
12.2 Alere
12.3 Atlas Medical
12.4 Beckman Coulter
12.5 Becton, Dickinson and Company
12.6 Bio-Rad Laboratories
12.7 bioMérieux
12.8 Creative Diagnostics
12.9 Danaher
12.10 DiaSorin
12.11 Guangzhou Wondfo Biotech
12.12 Lepu Medical Technology
12.13 Life Diagnostic
12.14 LSI Medience Corporation
12.15 Nectar Lifesciences
12.16 NanoEnteck
12.17 Ortho Clinical Diagnostic
12.18 PerkinElmer
12.19 Randox Laboratories
12.20 Roche Diagnostics
12.21 Thermo Fisher Scientific
12.22 Siemens Healthineers
13 Appendix
13.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • Alere
  • Atlas Medical
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • bioMérieux
  • Creative Diagnostics
  • Danaher
  • DiaSorin
  • Guangzhou Wondfo Biotech
  • Lepu Medical Technology
  • Life Diagnostic
  • LSI Medience Corporation
  • Nectar Lifesciences
  • NanoEnteck
  • Ortho Clinical Diagnostic
  • PerkinElmer
  • Randox Laboratories
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Siemens Healthineers